Vertex, Worth $7.5B, Eagerly Awaits Final Proof that Hepatitis C Drug Works

(Page 2 of 2)

been treated for hepatitis C infections, just like the earlier trial. The study, which enrolled 500 patients, is also looking to see how many clinical cures it can generate, and whether there’s any benefit in subjecting patients to the standard 48-week course of therapy, or whether they do just as well in half the time, Kauffman says. “It should validate that 24 weeks is enough,” Kauffman says.

The third study, called “Realize,” is important for strategic and competitive reasons. This trial enrolled 663 patients who had previously been treated for hepatitis C, but weren’t cured. Vertex has shown some promising results in this tough-to-treat patient population in the past, which is the sort of data that can really give physicians confidence in the drug’s punch. Vertex has taken care to stratify this study into three different kinds of patients—those who benefitted for a while but relapsed, those who only partially responded to prior therapy, and those who never really benefitted at all. Patients will get telaprevir in addition to the standard treatment, or just the standard stuff, for a total of 48 weeks.

As I described back in September 2008, this study is one of the key ways that Vertex seeks to differentiate itself from a competitors that are following fast—Merck’s boceprevir.

Kauffman declined to speculate on how high the clinical cure rates will need to be for Vertex to declare victory. Last October, Vertex presented results from patients who failed prior therapy, which demonstrated telaprevir could induce cure rates between 55 percent and 90 percent. Vertex said back in April 2008, before it invested in the pivotal round of telaprevir trials, that between 61 percent and 68 percent of treatment-naïve patients were clinically cured in the smaller trials (Prove 1 and Prove 2).

After the past two years of recruiting patients, supplying the clinical sites with experimental drugs, monitoring the sites to make sure they follow the study protocol, and gathering all the data, you could say the expectations are high for this study. Wall Street, after all, is giving Vertex that $7.5 billion market valuation on anticipation of telaprevir’s sales trajectory more than any other factor. If the pivotal studies confirm the smaller trials—which is never a given in drug development—you will probably hear the victory whoops skimming all the way across the Charles River from Vertex headquarters in Cambridge.

“Phase III is the ultimate confirmation,” Kauffman says. “They are the largest and most definitive studies. It’s a very important time for us at the company now.”

Single PageCurrently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

6 responses to “Vertex, Worth $7.5B, Eagerly Awaits Final Proof that Hepatitis C Drug Works”

  1. Telaprevir will be used in a “triple therapy” along with pegylated interferon and ribavirin. The problem is interferon. It is a very dangerous drug and has caused permanent nerve damage, memory problems and neuropsychiatric disorders to many people, including me. I wish the FDA would do an investigation on just how many people, were damaged by interferon. Do a google search. Read the Hepatitis C forums. You will see alot of people that was ok, before they started the treatment, and afterward was left with numerous debilitating medical problems. I wish I could sue the makers of this horrible drug interferon. It’s been two years since treatment and I live everyday in pain. Frustrated in Texas…..!

  2. unsure in Michigan says:

    That’s why I’m looking to join a clinical trial –one that doesn’t include interferon. All I here is negative info about it.

  3. Frank Mulder says:

    Could someone please contact me about Vertex Clinical Trials for Hep C. I cannot find one available. I live in Tampa, Florida. My phone number is 813 992-1970.

    Frank Mulder

  4. RonG says:

    I am literally dying with hepatic encephalopathy and have developed cirrhosis with ammonia levels that will not come down. I failed the interferon combo and the side effects were horrible, but I cannot wait to try this drug out with all the side effects. Transplant does not work as you become infected again. I am counting the minutes to try and trying to hold on. I want to go back to work, I want to not be sick, I want to grow old (I’m just 51). I would do anything to have my health back.

  5. J Dub says:

    I did a year on Peg-Intron (alph interferon 2-b). I’ve been in pain ever since. My legs have an excruciating vibration that never quits. It varies in intensity. At best it’s a very uncomfortable tremble in my lower legs. But most of the time it is much worse. Often consuming most of my entire body. Sometimes from my ribcage to my toes. My legs are also in constant pain. The vibration causes the muscles, tendons, and joints in my legs to hurt costantly, because they are always tense and trying to compensate. I’m just 58, I would also do anything to have my health back. I want my LIFE back. I have to go lay down now. Too much activity causes more pain. I wanna get out of bed, go to work. I want to go sailing again. But I doubt I ever will. Interferon screwed me up so much that IF I ever try another drug treatment and it doesn’t help me I hope it kills me. Sounds very dramatic, but that’s exactly how I feel. Depression was a battle during treatment. It’s worse now! I think about suicide. But it’s not an option, I have a family.

  6. Saumitra says:

    Luke , you could perhaps annotate this excellent article by adding this latest – not so good news on Telaprevir